Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy

ClinicalTrials.gov ID: NCT00321646

Public ClinicalTrials.gov record NCT00321646. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 3, 2026, 9:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study of Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of this trial is to collect information and to evaluate the effects, good or bad, the combination of docetaxel and bevacizumab has on patients with high risk prostate cancer that are undergoing radical prostatectomy.

Study identification

NCT ID: NCT00321646
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Mary-Ellen Taplin, MD; Other
Enrollment: 42 participants

Conditions and interventions

Conditions

Interventions

Bevacizumab Drug
Docetaxel Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Male
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 2006 (Type not available)
Primary completion: Nov 2008 (Actual)
Completion: Dec 2012 (Actual)
Last update posted: May 16, 2016

2006 – 2012

United States locations

U.S. sites: 3
U.S. states: 2
U.S. cities: 2

Facility	City	State	ZIP	Site status
Beth Israel Deaconess Medical Center	Boston	Massachusetts	02114	—
Dana-Farber Cancer Institute	Boston	Massachusetts	02115	—
Duke University Medical Center	Durham	North Carolina	27710	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00321646, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 16, 2016 · Synced Oct 3, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00321646 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →